Myovant Sciences - MYOV Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Myovant Sciences in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MYOV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYOV, but not buy additional shares or sell existing shares.
View MYOV analyst ratings or view top-rated stocks.

3 brokers have issued 1-year price objectives for Myovant Sciences' stock. Their MYOV share price forecasts range from $10.00 to $27.00. On average, they expect the company's share price to reach $21.33 in the next twelve months. This suggests that the stock has a possible downside of 20.6%.
View analysts price targets for MYOV or view top-rated stocks among Wall Street analysts.

Myovant Sciences' stock was trading at $15.57 at the beginning of 2022. Since then, MYOV shares have increased by 72.6% and is now trading at $26.88.
View the best growth stocks for 2022 here.

Myovant Sciences saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 2,070,000 shares, an increase of 18.3% from the October 31st total of 1,750,000 shares. Based on an average daily volume of 1,740,000 shares, the days-to-cover ratio is presently 1.2 days. Approximately 4.8% of the shares of the company are sold short.
View Myovant Sciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, January 25th 2023.
View our MYOV earnings forecast.

Myovant Sciences Ltd. (NYSE:MYOV) issued its earnings results on Wednesday, October, 26th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.02. The firm had revenue of $104.82 million for the quarter, compared to analyst estimates of $92 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Coty (COTY), Gilead Sciences (GILD), Micron Technology (MU), VBI Vaccines (VBIV), NVIDIA (NVDA) and Carnival Co. & (CCL).

(MYOV) raised $176 million in an IPO on Thursday, October 27th 2016. The company issued 13,000,000 shares at a price of $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

Myovant Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Bellevue Group AG (6.11%), State Street Corp (2.08%), BlackRock Inc. (1.23%), Vanguard Group Inc. (0.85%), Renaissance Technologies LLC (0.30%) and Hennion & Walsh Asset Management Inc. (0.28%). Insiders that own company stock include Chemical Co Ltd Sumitomo, David C Marek, Ferreira Juan Camilo Arjona, Frank Karbe, Kim Sablich, Lauren Merendino, Matthew Lang, Sciences Ltd Roivant and Uneek Mehra.
View institutional ownership trends.

Shares of MYOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MYOV stock can currently be purchased for approximately $26.88.

Myovant Sciences (NYSE:MYOV) has a market capitalization of $2.60 billion and generates $230.97 million in revenue each year. The company earns $-205,980,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis.

The company employs 407 workers across the globe.

Myovant Sciences' mailing address is 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The official website for the company is www.myovant.com. The company can be reached via phone at 442074003351 or via email at investors@myovant.com.